<DOC>
	<DOCNO>NCT01871454</DOCNO>
	<brief_summary>The objective prospective phase II protocol ass toxicity efficacy pentoxifylline SABR re-treatment recurrent new lung cancer</brief_summary>
	<brief_title>Safety Pentoxifylline Vitamin E With Stereotactic Ablative Radiotherapy ( SABR ) Non-small Cell Lung Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>3.1 Eligibility Criteria 3.1.1 Age &gt; /= 18 year 3.1.2 ECOG performance status 01 3.1.3 Histologically proven diagnosis prior thoracic malignancy treat thoracic external beam radiotherapy without systemic chemotherapy 3.1.4 Pathologic clinical diagnosis new locoregional recurrent lung malignancy . A reasonable attempt make make pathologic diagnosis malignancy ( ie . bronchoscopy , CT guide lung biopsy ) Locoregional define recurrence within region primary tumor adjacent drain lymph node region . The new lesion locoregional recurrence must within adjacent previously irradiate treatment volume . 3.1.5 Imaging follow : CT scan chest IV contrast within 8 week registration Whole body PET scan within 8 week registration 3.1.6 Pulmonary function test ( PFTs ) , include diffusion capacity within 8 week registration 3.1.7 Negative serum pregnancy test within 2 week prior registration woman childbearing potential . 3.1.6 Women childbearing potential male participant sexually active must agree use medically effective mean birth control 3.1.7 Patients must provide study specific informed consent prior study entry . 3.2 Exclusion Criteria 3.2.1 . No previously report thoracic radiotherapy 3.2.2 . FEV1 &lt; 20 % predict and/or DLCO &lt; 20 % predict 3.2.2 . Pregnant woman lactate woman 3.2.3 Chemotherapy within 4 week initiation SABR 3.2.4 Plans administer systemic chemotherapy overlap radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>